Patents Examined by Dameron L. Jones
  • Complex and method for producing epoxides by using the complex
    Patent number: 6833442
    Abstract: There is provided a complex having a specified chemical structure and an asymmetric catalyst using such a complex. Further, an epoxidation of amine or ketone is enantioselectively conducted by using such an asymmetric catalyst.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: December 21, 2004
    Assignee: The University of Tokyo
    Inventors: Masakatsu Shibasaki, Takashi Ohshima, Tetsuhiro Nemoto
  • Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof
    Patent number: 6827925
    Abstract: Specific binding members, based on the third CDR of the antibody NHS76 (SEQ ID NO: 2) are provided, together with their use in methods of treatment and diagnosis.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: December 7, 2004
    Assignee: Cambridge Antibody Technology Limited
    Inventors: Andrew James Williams, Philip Ronald Tempest, Thor Las Holtet, Helen Jackson
  • Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
    Patent number: 6824759
    Abstract: This invention relates to a radiodiagnostic agent to image tumors. A composition for a tumor imaging agent, a method and kit for preparing a tumor imaging agent, and a radiolabeling reagent for preparing the tumor imaging agent are provided.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 30, 2004
    Assignees: Thomas Jefferson University, Temple University - of the Commonwealth System of Higher Education
    Inventors: Madhukar L. Thakur, M. V. Ramana Reddy
  • Detection of alzheimer's amyloid by magnetic resonance imaging
    Patent number: 6821504
    Abstract: Alzheimer's disease can be diagnosed in vivo using magnetic resonance imaging. A labeled A&bgr; peptide or its derivative is injected into the patient to be diagnosed, after which the patient is subjected to magnetic resonance imaging. Both pre-amyloid and amyloid plaques can be detected using this method.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: November 23, 2004
    Assignee: New York University
    Inventors: Thomas Wisniewski, Daniel Turnbull, Einar Sigurdsson, Youssef Zaim Wadghiri
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6818201
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: November 16, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Edward H. Cheesman, Michael Sworin, Milind Rajopadhye
  • Diagnostic imaging agent useful for selecting a therapy for cancerous bone metastasis
    Patent number: 6814952
    Abstract: A diagnostic imaging agent useful for selection of a therapy for cancerous bone metastasis is provided, which comprises 99mTc(V)-dimercaptosuccinic acid as an effective ingredient. The agent is administered to a patient, and a scintigram is taken. This is especially useful for identifying osteoclastic type or mixed type bone metastasis or for identifying a disease in which the bone resorption due to osteoclast is enhanced, and thus allows a proper selection of therapies for such diseases.
    Type: Grant
    Filed: September 18, 2001
    Date of Patent: November 9, 2004
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Kazuko Horiuchi Suzuki, Hideo Saji, Akira Yokoyama
  • Methods for imaging pulmonary and cardiac vasculature and evaluating blood flow using dissolved polarized 129Xe
    Patent number: 6808699
    Abstract: MR spectroscopy and imaging methods for imaging pulmonary and cardiac vasculature and the cardiac region and evaluating blood flow or circulatory deficits use dissolved phase polarized 129Xe gas and large flip angle excitation pulses. Pulmonary and cardiac vasculature MRI images are obtained by delivering gas to a patient via inhalation such as with a breath-hold delivery-procedure, exciting the dissolved phase gas with a large flip angle pulse, and generating a corresponding image. Preferably, the image is obtained using multi-echo imaging techniques. Blood flow is quantified using low field MR spectroscopy and an RF excitation pulse with a frequency which corresponds to the resonance of the dissolved phase 129Xe.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: October 26, 2004
    Assignee: Medi-Physics, Inc.
    Inventors: Bastiaan Driehuys, Kenton Christopher Hasson, Paul Lev Bogorad
  • Method for localization of blood clots
    Patent number: 6808698
    Abstract: A method wherein a radiolabelled compound is localized at a thrombus. Two-dimensional images, representing a physical property associated with the radiolabelled thrombus, are acquired and assembled into a three-dimensional matrix of data. The three-dimensional matrix of data is then scanned along an array of parallel lines to determine a maximum value along each line. The maximum value along each line is then assigned to a pixel in a two-dimensional array, where the relative position of the pixel in the two-dimensional array corresponds to the relative position of the line in the array of parallel lines.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: October 26, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Joel Lazewatsky
  • Pharmaceuticals for the imaging of angiogenic disorders
    Patent number: 6800273
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: October 5, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D. Harris, Stuart J. Heminway, Shuang Liu, Prahlad R. Singh
  • Magnetic resonance imaging agents for the detection of physiological agents
    Patent number: 6770261
    Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
    Type: Grant
    Filed: May 24, 2001
    Date of Patent: August 3, 2004
    Assignee: Research Corporation Technologies
    Inventors: Thomas J. Meade, Scott Fraser
  • Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
    Patent number: 6770259
    Abstract: The present invention provides novel diagnostic compositions comprising a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, diagnostic kits comprising such compositions, and methods of concurrent imaging in a mammal comprising administering a radiolabeled LTB4 binding agent and a radiolabeled perfusion imaging agent, and concurrently detecting the radiolabeled LTB4 binding agent bound at the LTB4 receptor and the radiolabeled perfusion imaging agent.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: August 3, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Alan P. Carpenter, Jr.
  • High dose radionuclide complexes for bone marrow suppression
    Patent number: 6767531
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: July 27, 2004
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Pathological tissue detection and treatment employing targeted benzoindole optical agents
    Patent number: 6761878
    Abstract: Novel tumor specific phototherapeutic and photodiagnostic agents are disclosed. The compounds consist of a carbocyanine dye for visualization, photosensitizer for photodynamic treatment, and tumor receptor-avid peptide for site-specific delivery of the probe and phototoxic agent to diseased tissues A combination of these elements takes full advantage of the unique and efficient properties of each component for an effective patient care management.
    Type: Grant
    Filed: October 17, 2001
    Date of Patent: July 13, 2004
    Assignee: Mallinckrodt, Inc.
    Inventors: Samuel Achilefu, Richard B. Dorshow, Raghavan Rajagopalan, Joseph E. Bugaj
  • Methods for treating AVM's using radioactive compositions
    Patent number: 6759028
    Abstract: Disclosed are methods for treating AVMs in a mammal by use of a radiation composition.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: July 6, 2004
    Assignee: Micro Therapeutics, Inc.
    Inventors: George Wallace, Richard J. Greff
  • Magnetic fluids
    Patent number: 6749844
    Abstract: A magnetic fluid is provided comprising a block copolymer stabilizer, magnetic particles and a fluid polysiloxane medium. The stabilizer comprises an anchor block which chelates magnetic metal particles, and at least one end block which is compatible with the polysiloxane medium.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 15, 2004
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Judy S. Riffle, Janice Paige Phillips, James P. Dailey
  • Labelled ascorbic acid derivatives
    Patent number: 6749832
    Abstract: Compounds of formula (I) where: X1 is OH or SH or NH2 or —L-Z; X2 and X3 are the same or different and each is H, C1-4 alkyl, benzyl a protecting group or —L-Z, X4 is H or C1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: June 15, 2004
    Assignee: Amersham PLC
    Inventors: Susan Champion, Richard Pither
  • Azo compounds for type I phototherapy
    Patent number: 6747151
    Abstract: Novel azo compounds and their bioconjugates for phototherapy and/or photodiagnosis of tumors and other lesions. The azo derivatives of the present invention are designed to absorb at the low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photoexcitation of the azo compound, with the tissue of interest.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: June 8, 2004
    Assignee: Mallinckrodt, Inc.
    Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Joseph E. Bugaj, Samuel I. Achilefu, Richard B. Dorshow
  • Porphyrin compounds
    Patent number: 6746663
    Abstract: The present invention provides the porphyrin compound which is used for photodynamic diagnosis and/or treatment for animals, and the photodynamic diagnostic and/or therapeutic agent for animals.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: June 8, 2004
    Assignee: Photochemical Co., Ltd.
    Inventors: Isao Sakata, Susumu Nakajima, Yoshinori Nakae
  • Vitronectin receptor antagonist pharmaceuticals
    Patent number: 6743412
    Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 1, 2004
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Thomas D. Harris, Milind Rajopadhye
  • Extracorporal system for treating disease with radionucleotides
    Patent number: 6743411
    Abstract: A composition of matter comprises a pathogen-targeting organic moiety which is conjugated to a radioisotope which has a half-life of less than 100 days. The composition can be synthesized by bringing together a radioisotope having a half life of less than 100 days with a greater than stoichiometric amount of a complexing agent so as to form a first mixture containing a reaction product between the radioisotope and the complexing agent; removing the excess complexing agent from the mixture; and bringing together the first reaction product and an antibody substance so as to form a second mixture containing a reaction product between the first reaction product and the antibody substance. The composition is deposited on a particulate substrate and is useful for treating infectious diseases caused by pathogens by passing the patients blood through a bed formed from the particles.
    Type: Grant
    Filed: August 24, 2001
    Date of Patent: June 1, 2004
    Assignee: RX/IBR Corporation
    Inventor: Arthur Dale Ericsson